

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beauty Farm Medical and Health Industry Inc.

美麗田園醫療健康產業有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2373)

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING IN THE COMPANY BY A DIRECTOR; AND ON-MARKET SHARE REPURCHASE

This announcement is made by Beauty Farm Medical and Health Industry Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

INCREASE IN SHAREHOLDING IN THE COMPANY BY A DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of the Company was informed by Ms. Yi Lin, a non-executive director of the Company, that as at October 24, 2025, she has purchased a total of 61,000 ordinary shares of the Company (“**Share**”), representing approximately 0.03% of the total issued Shares as at the date of this announcement, on the open market transactions with her own funds, demonstrating her firm belief and strong confidence in the future development prospects of the Group. Ms. Yi Lin currently serves as a partner at Defu Capital, with over 20 years of experience in investment and financing, investor relations and financial management. In August of this year, Ms. Yi Lin joined the Board as a representative of Defu Capital, one of the two major capital investors introduced by the Company in the first half of the year. The increase in shareholding by Ms. Yi Lin further underscores the firm belief of high-quality long-term capital investors in the Group’s future prospects.

ON-MARKET SHARE REPURCHASE

The Company is pleased to announce that on October 30, 2025, it repurchased 30,000 shares of the Company (the “**Share Repurchases**”) on the market for a total transaction amount of approximately HK\$927,150, at an average transaction price of approximately

* For identification purposes only

HK\$30.91 per share. Between October 15, 2025 and the date of this announcement, a total of 475,000 shares of the Company have been repurchased, for a total consideration of approximately HK\$15,069,220.

The Board considers that the current trading price of the shares does not reflect their intrinsic value and the actual business prospects of the Company. The Board believes that the share repurchase reflects the management's firm confidence in the long-term value of the enterprise and is conducive to enhancing the Group's capital market value and its ability to deliver returns to shareholders. This share repurchase is in the interests of the Company and its shareholders as a whole.

The Board conducted this share repurchase under the general mandate to repurchase the Shares ("**Repurchase Mandate**") granted by resolution of the shareholders (the "**Shareholders**") passed in the annual general meeting (the "**AGM**") of the Company held on June 27, 2025. Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 23,579,556 shares being 10% of the number of Shares in issue as at the date of the AGM.

Based on the public information available to the Company and as far as the Board is aware, following the increase in Ms. Yi Lin's shareholding in the Company and the Share Repurchases, and as at the date of this announcement, the Company has continued to maintain sufficient public float of the issued Shares in compliance with Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors of the Company are advised that the repurchase of Shares is subject to the sole discretion of the Directors based on the market conditions and that no assurance can be given as to the timing, quantity or price of any repurchase. As such, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Beauty Farm Medical and Health Industry Inc.
Li Yang
Chairman and executive Director

Hong Kong, October 31, 2025

As at the date of this announcement, the Board comprises Mr. Li Yang as Chairman and executive director, Mr. Lian Songyong as Vice Chairman and executive director, Ms. Li Fangyu, Mr. Gao Jianming and Ms. Yi Lin as non-executive directors and Mr. Fan Mingchao, Mr. Liu Teng and Mr. Jiang Hua as independent non-executive directors.